Zinc oxide nanoparticles mitigate the malignant progression of ovarian cancer by mediating autophagy-dependent ferroptosis Authors: Wenli Gu, Caihong Yang Published: 2024 ABSTRACT BackgroundPrevious studies have shown that ZnO-NPs induce autophagy and inhibit the malignant progression of ovarian cancer (OC) cells. This study aims to further explore the mechanism of action of ZnO-NPs on OC.MethodsSKOV3 cells were treat with different concentrations of ZnO-NPs and cell proliferation was assessed through EDU staining. A Xenograft tumor model was established and mice were treated with varying doses of ZnO-NPs for 21 days. Tumor volume and the weight of each group of mice were measured, and the expression of KI67 in tumor tissues was analyzed to evaluate tumor proliferation in vivo. The expression of autophagy and ferroptosis-related proteins in cells and tumor tissues was examined through immunofluorescence, ELISA, and western blotting assays. The relationship between ZnO-NPs induced autophagy and ferroptosis was further investigated using the ferroptosis inhibitors Fer-1, autophagy inhibitor 3-MA and siRNA for ATG5 (si-ATG5).ResultsZnO-NPs dose-dependently reduced the proliferation of SKOV3 cells in vitro. In vivo, both high and low doses of ZnO-NPs effectively inhibited the growth of tumor, reduced pathological damage and the expression of KI67 in tumor tissues. Additionally, ZnO-NPs increased the levels of iron, MDA, 4-HNE, oxidized lipid ROS, ATG5, TFR1, ACSL4, LC3, and Beclin1 in cells and tumor tissues, decreased the expression of SOD, GSH-Px, non-oxidized lipid ROS, GPX4, and p62. Transfection with si-ATG5 or treatment with 3-MA significantly weakened these effects of ZnO-NPs in vitro, with si-ATG5 having a stronger weakening effect on the action of ZnO-NPs than 3-MA. However, ferroptosis inhibitor has a lesser impact on the autophagy of ZnO-NPs-treated SKOV3 cells than the effect of autophagy inhibitors and si-ATG5 on the ferroptosis of ZnO-NPs-treated SKOV3 cells.ConclusionZnO-NPs inhibited the malignant progression of SKOV3 cells by inducing autophagy-dependent ferroptosis. Introduction Ovarian cancer (OC) is a prevalent malignant tumor affecting the female reproductive system, with a high mortality rate (Penny 2020). In China in 2022, there were around 57,000 new cases and 39,000 deaths from OC (Xia et al. 2022). Currently, the primary treatment methods for clinical OC include surgery combined with radiotherapy, chemotherapy, targeted therapy, and immunotherapy (Morand et al. 2021; Orr and Edwards 2018). However, due to the lack of specific biomarkers and typical clinical symptoms, patients are often diagnosed at advanced stages, leading to a low 5-year survival rate of under 30% (Temkin et al. 2022; Antonio et al. 2022). Additionally, about 80% of OC patients also experience a decrease in chemotherapy effectiveness due to the development of chemotherapy resistance (Ortiz et al. 2022). Therefore, there is a need to explore new strategies and drugs to improve the prognosis and increase survival rates for OC patients. Zinc oxide nanoparticles (ZnO-NPs) is a commonly used nanomaterial in engineering. It has been found to have specific toxicity towards cancer cells by generating reactive oxygen species and disrupting the mitochondrial membrane potential (Anjum et al. 2021). Previous research has shown that ZnO-NPs can reduce the expression of markers related to cell proliferation in OC cells and induce cell apoptosis (Gu et al. 2022). Additionally, ZnO-NPs can hinder the advancement and resistance to chemotherapy in OC cells by triggering endoplasmic reticulum stress and promoting autophagy (Gu and Yang 2023). It is important to note that in other types of tumors, the impact of ZnO-NPs on the apoptosis and drug resistance of cancer cells has been shown to be linked to the regulation of autophagy (Yang et al. 2021; Miao et al. 2021; Li et al. 2024). This indicates that the ability of ZnO-NPs to combat cancer may be closely tied to their ability to activate autophagy. Autophagy is a conservative protein degradation pathway unique to eukaryotes, and its role in tumor development is dual-sided (Zhu et al. 2024). Ferroptosis is characterized by iron overload and lipid peroxidation accumulation (Dixon et al. 2012). Since its discovery, it has provided a new perspective for the treatment of various diseases. Studies suggest that inducing autophagy-dependent ferroptosis (ADF) may be a new anti-tumor strategy (Liu et al. 2020). More importantly, research has reported that ZnO-NPs can promote autophagy and ferroptosis in macrophages infected with Mycobacterium tuberculosis (Geng et al. 2023). In addition, studies have confirmed that the promotion of ferroptosis in vascular endothelial cells by ZnO-NPs is autophagy-dependent, and inhibiting autophagy significantly alleviated ZnO-NPs induced ferroptosis (Qin et al. 2021). However, whether the induction of autophagy by ZnO-NPs in OC cells will further affect ferroptosis in OC cells remains to be seen. Therefore, this study further explores the regulation of ZnO-NPs on autophagy and ferroptosis in OC cells. It also verifies the role of ZnO-NPs in inhibiting the malignant progression of tumors in vivo. The objective is to uncover the anti-tumor activity of ZnO-NPs in OC, providing a new theoretical foundation for the clinical application of ZnO-NPs. Materials and methods Cell culture and treatment The human OV cell line SKOV3 (YS2383C) was obtained from YaJi Biological and grown in culture following the methods outlined in a prior research study (Gu and Yang 2023). ZnO-NPs were synthesized and evaluated as previously described (Gu et al. 2022). SKOV3 cells were treatment with 10 µg/mL, 20 µg/mL, and 30 µg/mL ZnO-NPs for 24 h according to previous study results. To further investigate the relationship between ZnO-NPs induced autophagy and ferroptosis, SKOV3 cells were treated with the ferroptosis inhibitors Ferrostatin-1 (Fer-1, 1 µM) for 1 h, autophagy inhibitor 3-methyladenine (3-MA, 2 mM) for 24 h or transfected with small interfering RNA (siRNA) for ATG5 (Gene Pharma, China). For cell transfection, SKOV3 cells were inoculated into 6-well plates (2 × 105) and transfected with si-ATG5 (si-ATG5#1, 5’-CCTTTCATTCAGAAGCTGTTT-3’; si-ATG5#2, 5’-CATCTGAGCTACCCGGATA-3’) or control si-NC (5’-UUCUCCGAACGUCACGA-3’) using Lipofectamine 2000 for 6 h and then cultured in complete media for 48 h. EDU staining The proliferation ability of SKOV3 cells were assessed using a EDU Assay Kit (C0081S, Beyotime, China). In brief, SKOV3 cells were treatment with 20 mmol/L EDU for 2 h and then fixed with 4% paraformaldehyde for 20 min. Then, cells were incubated with 1% Triton X-100 for 15 min and Click reaction solution for 30 min in the dark. The results were captured by fluorescence microscope. Detection of iron The levels of iron were detected by a cell Fe2+ Assay Kit (E-BC-F101, Elabscience). SKOV3 cells (1 × 105) were cultured on sterilized coverslips and treated with 1 mL Probe solution (2 mmol/L) at 37 °C for 1 h in the dark. Then, cells were washed by Buffer solution and observed under a luorescence microscope (Ex/Em = 542 / 570 nm). Detection of lipid ROS The lipid ROS levels of SKOV3 cells were assessed using the C11 BODIPY 581/591 probe (MX5211, maokangbio). SKOV3 cells were stained with 5 µM BODIPY™ 581/591 C11 at 37 ◦C for 30 min. After being rinsed and resuspended in PBS, cells were stained with DAPI. The results were observed under a luorescence microscope (Ex/Em = 581/591 nm). Xenograft tumor model BALB/C nude mice (SPF-grade,18–22 g) obtained from the Ningxia medical university laboratory animal center were subcutaneously injection with 10 µL of SKOV3 cell suspension (5 × 108 cells/mL) to establish Xenograft tumor models. Seven days after cell implantation, the mice bearing tumors were randomized into a control group, a high-dose ZnO-NPs group and a low-dose ZnO-NPs group. Mice in the high-dose (20 mg/kg) and low-dose (10 mg/kg) ZnO-NPs groups were received intraperitoneal injections of ZnO-NPs once daily. ZnO-NPs of different doses were dispersed in deionized water and resuspended by ultrasonic vibration for 30 min, and ZnO-NPs suspensions were vortexed for 1 min before each administration. Mice in the control were treated with equal amount of solvent. The growth and size of the tumor in the mice were observed every three days for 21 days, and then euthanized. Then dissected the tumors, measured the tumor weight and volume. The tumor volume was calculated using the standard formula: Volume (mm3) = width2 (mm2) × length (mm) ×0.5. This study was approved by the Animal Ethics Committee of the General Hospital of Ningxia Medical University [KYLL-2024-0749]. Hematoxylin & eosin staining The tumor tissues were fixed with formalin and embedded in paraffin. Then, tumor tissues were cut in 4-µm slices and dehydrated, followed by stained with hematoxylin and eosin solution. The results were examined under an optical microscope. Immunohistochemistry (IHC) The paraffin sections of tumor tissues were dewaxed and dehydrated for antigen repair. The slides were incubated with anti-KI67 (1:150) at 4 °C overnight and washed with PBS. Then the sections were incubated with goat anti-rabbit IgG (1:2000) for 15 min followed by stained with DAB solution for 5 min. Finally, the sections were sealed by neutral resin and the images were captured by a microscope (DS-Ri2, Nikon). Prussian blue staining The prussian blue (PB) staining (60533ES60, YEASEN) was employed to detect iron deposition in tumor tissues. Tumor tissues were fixed in Fixation Buffer and embedded in paraffin, followed by cutting in 4-µm slices. Deparaffinized sections were stained with Perls’ stain for 30 min, and Nuclear Fast Red solution for 5 min. The sections were sealed and observed under a microscope. Immunofluorescence SKOV3 cells were seeded on sterilized coverslips and then fixed with 4% paraformaldehyde followed by permeabilized with 0.5% Triton X-100 for 15 min. The paraffin sections of tumor tissues were dewaxed and dehydrated for antigen repair. Then cells and sections were incubated with anti-LC3 (1:200, ab48394, Abcam), anti-ATG5 (1:200, ab108327, Abcam) or anti-NCOA4 (1:200, ab48394, Abcam) at 4 °C overnight, then were incubated with secondary antibody conjugated to fluorescein isothiocyanate for 1 h in the dark. Finally, cells were stained with DAPI and observed under a fluorescence microscope. Enzyme-linked immunosorbent assay (ELISA) The tumor tissues were cut into small pieces and homogenized in PBS at 4 °C. Then subsequent centrifugation at 1500 x g for a duration of 20 min to obtain the supernatant. SKOV3 cells were centrifuged at 1000 x g for 10 min at 4˚C to collect the supernatant. The levels of 4-HNE, MDA, SOD and GSH-Px in the supernatant were measured by a ELISA assay kit (Nanjing Jiancheng). Western blotting (WB) assay The total proteins form SKOV3 cells and tumor tissues were extracted by RIPA lysis buffer (Beyotime) containing protease inhibitors, and quantified with BCA Protein Assay Kit (epizyme). 30 µg of protein sample s were separated by 12% SDS-PAGE and then transferred to PVDF membranes. The membranes were incubated with primary antibodies at 4˚C overnight after blocking with 5% BSA and subsequently incubated with secondary antibody (ab6721, 1:5,000, Abcam) for 1 h. An Enhanced ECL Kit (Yeasen) was used to visualize the protein bands and the band intensity was measured with ImageJ software. The primary antibodies including: anti-LC3 (1:1000, ab192890, Abcam), anti-Beclin1 (1:1000, ab207612, Abcam), anti-p62 (1:1000, ab109012, Abcam), anti-GPX4 (1:1000, ab41787, Abcam), anti-ACSL4 (1:1500, ab155282, Abcam), anti-TFR1 (1:1500, AF5343, Affinity), anti-ATG5 (1:1000, ab108327, Abcam), anti-NCOA4 (1:1000, ab48394, Abcam) and anti-GAPDH (1:1000, ab8245, Abcam). Statistical analysis The data was analyzed by GraphPad Prism 8 software and showed in the format of mean ± standard deviation (SD). The unpaired student’s t-test was employed to compare the significance between two groups, a One-way ANOVA was performed accompanied by Tukey’s post hoc test was used to compare three or more groups. p < 0.05 means statistically significant difference. Results ZnO-NPs inhibit the proliferation of SKOV3 cells both in vitro and in vivo Firstly, we investigated the effects of ZnO-NPs on SKOV3 cell proliferation in vitro and in vivo. The results showed that ZnO-NPs dose-dependently reduced the proliferation of SKOV3 cells in vitro (Fig. 1A). Meanwhile, both 10 mg/mL and 20 mg/mL ZnO-NPs effectively inhibited the growth of SKOV3 cells in vivo (Fig. 1B). In the absence of significant differences in body weight (Fig. 1C), the tumor weight (Fig. 1D) and volume (Fig. 1E) of mice in the 10 mg/mL and 20 mg/mL ZnO-NPs groups were significantly reduced. In addition, ZnO-NPs reduced the degree of pathological damage (Fig. 1F) and decreased the expression of KI67 (Fig. 1G) in tumor tissues. Fig. 1ZnO-NPs inhibit the proliferation of SKOV3 cells both in vitro and in vivo. ZnO-NPs dose-dependently reduced the proliferation of SKOV3 cells in vitro (A). ZnO-NPs inhibited the growth of SKOV3 cells in vivo (B). The body weight (C), tumor weight (D) and tumor volume (E) of mice in each group. HE staining showing the degree of pathological damage (F). Immunohistochemistry detected the expression of KI67 in tumor tissues (G). *P < 0.05, **P < 0.01, ***P < 0.001 vs. Control ZnO-NPs inhibit the proliferation of SKOV3 cells both in vitro and in vivo. ZnO-NPs dose-dependently reduced the proliferation of SKOV3 cells in vitro (A). ZnO-NPs inhibited the growth of SKOV3 cells in vivo (B). The body weight (C), tumor weight (D) and tumor volume (E) of mice in each group. HE staining showing the degree of pathological damage (F). Immunohistochemistry detected the expression of KI67 in tumor tissues (G). *P < 0.05, **P < 0.01, ***P < 0.001 vs. Control ZnO-NPs promote ferroptosis in SKOV3 cells and tumor tissues Subsequently, we examined the levels of ferroptosis in SKOV3 cells and tumor tissues. The findings indicated that the contents of iron (Fig. 2A), lipid peroxides MDA, and 4-HNE were elevated in SKOV3 cells in a manner dependent on ZnO-NPs compared to controls. Moreover, the levels of antioxidants SOD and GSH-Px decreased as the doses of ZnO-NPs increased (Fig. 2B). Additionally, ZnO-NPs led to a dose-dependent increase in oxidized lipid ROS levels and a decrease in non-oxidized lipid ROS levels (Fig. 2C). Furthermore, the expression of ferroptosis-related proteins TFR1 and ACSL4 was enhanced by ZnO-NPs, while the expression of GPX4 protein was reduced in SKOV3 cells (Fig. 2D). Fig. 2ZnO-NPs promote ferroptosis in SKOV3 cells. The content of iron in SKOV3 cells (A). The levels of MDA, 4-HNE, SOD and GSH-Px in SKOV3 cells (B). The levels of oxidized ROS and non-oxidized ROS in SKOV3 cells (C). The expression of ferroptosis-related proteins TFR1, ACSL4, GPX4 in SKOV3 cells (D). **P < 0.01, ***P < 0.001 vs. Control ZnO-NPs promote ferroptosis in SKOV3 cells. The content of iron in SKOV3 cells (A). The levels of MDA, 4-HNE, SOD and GSH-Px in SKOV3 cells (B). The levels of oxidized ROS and non-oxidized ROS in SKOV3 cells (C). The expression of ferroptosis-related proteins TFR1, ACSL4, GPX4 in SKOV3 cells (D). **P < 0.01, ***P < 0.001 vs. Control In vivo experiments showed that there was a increase in the formation of Prussian blue deposits (Fig. 3A) and an elevate in MDA and 4-HNE levels in tumor tissues in both the high and low dosage groups of ZnO-NPs (Fig. 3B). Moreover, compared to the control group, the levels of ferroptosis-related proteins TFR1 and ACSL4 were elevated, while the expression of GPX4 was reduced in the group treated with ZnO-NPs (Fig. 3C). Fig. 3ZnO-NPs promote ferroptosis in tumor tissues. The content of iron in tumor tissues (A). The levels of MDA and 4-HNE in tumor tissues (B). The expression of ferroptosis-related proteins TFR1, ACSL4 and GPX4 in tumor tissues (C). **P < 0.01, ***P < 0.001 vs. Control ZnO-NPs promote ferroptosis in tumor tissues. The content of iron in tumor tissues (A). The levels of MDA and 4-HNE in tumor tissues (B). The expression of ferroptosis-related proteins TFR1, ACSL4 and GPX4 in tumor tissues (C). **P < 0.01, ***P < 0.001 vs. Control ZnO-NPs induce autophagy in SKOV3 cells and tumor tissues Next, we examined the levels of autophagy related indicators in both SKOV3 cells and tumor tissues. The results showed that the fluorescence intensity of LC3 was enhanced in a dose-dependent manner with ZnO-NPs compared with the control group (Fig. 4A). WB analysis revealed that the levels of proteins associated with autophagy and ferritinophagy, such as ATG5, NCOA4, and Beclin1, increased in SKOV3 cells as the dose of ZnO-NPs increased. Conversely, the levels of p62 consistently decreased (Fig. 4B). Fig. 4ZnO-NPs induce autophagy and ferritinophagy in SKOV3 cells and tumor tissues. The fluorescence intensity of LC3 in SKOV3 cells (A). The expression of autophagy and ferritinophagy related protein ATG5, NCOA4, Beclin1, and p62 in SKOV3 cells (B). The fluorescence intensity of ATG5 (C) and NCOA4 (D) in tumor tissues. The protein expression of LC3, ATG5, NCOA4, Beclin1 and p62 in tumor tissues (E). *P < 0.05, **P < 0.01, ***P < 0.001 vs. Control ZnO-NPs induce autophagy and ferritinophagy in SKOV3 cells and tumor tissues. The fluorescence intensity of LC3 in SKOV3 cells (A). The expression of autophagy and ferritinophagy related protein ATG5, NCOA4, Beclin1, and p62 in SKOV3 cells (B). The fluorescence intensity of ATG5 (C) and NCOA4 (D) in tumor tissues. The protein expression of LC3, ATG5, NCOA4, Beclin1 and p62 in tumor tissues (E). *P < 0.05, **P < 0.01, ***P < 0.001 vs. Control Similarly, compared to the control group, the fluorescence intensity of ATG5 (Fig. 4C) and NCOA4 (Fig. 4D) in tumor tissues was increased after ZnO-NPs treatment. The protein expression of LC3, ATG5, NCOA4, and Beclin1 was increased, while the expression of p62 protein was decreased in ZnO-NPs treatment groups (Fig. 4E). Notably, the expression of ATG5 showed the most prominent increase in SKOV3 cells and tumor tissues after ZnO-NPs treatment. ZnO-NPs mediate ferroptosis in SKOV3 cells via autophagy, which is associated with ATG5 Finally, the impact of ZnO-NPs induced autophagy on ferroptosis in SKOV3 cells was further investigated by autophagy inhibitors 3-MA and siRNA for ATG5. WB results revealed that both si-ATG5#1 and si-ATG5#2 significantly decreased the expression of ATG5 in SKOV3 cells, with si-ATG5#2 showing better interference efficiency (Fig. 5A). Therefore, si-ATG5#2 were used for further investigation. The findings indicated that the use of si-ATG5 and 3-MA led to a reduction in iron (Fig. 5B), MDA, and 4-HNE levels in SKOV3 cells, while increasing SOD and GSH-Px content compared to ZnO-NPs group (Fig. 5C). Moreover, in the compared to ZnO-NPs + si-ATG5 and compared to ZnO-NPs + 3-MA groups, there was a decrease in oxidized lipid ROS and an increase in non-oxidized lipid ROS in SKOV3 cells (Fig. 5D). WB analysis revealed that TFR1 and ACSL4 protein expression was decreased, while GPX4 protein expression was increased in SKOV3 cells in the ZnO-NPs + si-ATG5 and ZnO-NPs + 3-MA groups compared to the ZnO-NPs group (Fig. 5E). Additionally, the inhibition of ferroptosis effect was more pronounced in the ZnO-NPs + si-ATG5 group than in the ZnO-NPs + 3-MA group. Fig. 5ZnO-NPs mediate ferroptosis in SKOV3 cells via autophagy, which is associated with ATG5. The interference efficiency of si-ATG5#1 and si-ATG5#2 (A). The content of iron in SKOV3 cells (B). The levels of MDA, 4-HNE, SOD and GSH-Px in SKOV3 cells (C). The levels of oxidized ROS and non-oxidized ROS in SKOV3 cells (D). The expression of ferroptosis-related proteins TFR1, ACSL4, GPX4 in SKOV3 cells (E). ***P < 0.001 vs. Control, #P < 0.05, ##P < 0.01, ###P < 0.001 vs. ZnO-NPs ZnO-NPs mediate ferroptosis in SKOV3 cells via autophagy, which is associated with ATG5. The interference efficiency of si-ATG5#1 and si-ATG5#2 (A). The content of iron in SKOV3 cells (B). The levels of MDA, 4-HNE, SOD and GSH-Px in SKOV3 cells (C). The levels of oxidized ROS and non-oxidized ROS in SKOV3 cells (D). The expression of ferroptosis-related proteins TFR1, ACSL4, GPX4 in SKOV3 cells (E). ***P < 0.001 vs. Control, #P < 0.05, ##P < 0.01, ###P < 0.001 vs. ZnO-NPs Meanwhile, we examined the effect of the ferroptosis inhibitor Fer-1 on the autophagy of SKOV3 cells induced by ZnO-NPs. The results indicated that the addition of Fer-1 significantly reduced the iron levels in SKOV3 cells compared to the ZnO-NPs group (Fig. 6A). However, the fluorescence intensity of LC3 in the ZnO-NPs + Fer-1 group of SKOV3 cells did not exhibit significant differences when compared to the ZnO-NPs group (Fig. 6B). The result of WB assay showed that the expression levels of ATG5, NCOA4 and Beclin1 were obviously decreased in the ZnO-NPs + Fer-1 group in contrast to the ZnO-NPs group, and the expression of p62 also showed an increasing trend (Fig. 6C). Fig. 6Ferroptosis inhibitor has a lesser impact on the autophagy of ZnO-NPs-treated SKOV3 cells than the effect of autophagy inhibitors and si-ATG5 on the ferroptosis. The content of iron in SKOV3 cells (A). The fluorescence intensity of LC3 in SKOV3 cells (B). The expression of autophagy and ferritinophagy related protein ATG5, NCOA4, Beclin1, and p62 in SKOV3 cells (C). ***P < 0.001 vs. Control, #P < 0.05 vs. ZnO-NPs Ferroptosis inhibitor has a lesser impact on the autophagy of ZnO-NPs-treated SKOV3 cells than the effect of autophagy inhibitors and si-ATG5 on the ferroptosis. The content of iron in SKOV3 cells (A). The fluorescence intensity of LC3 in SKOV3 cells (B). The expression of autophagy and ferritinophagy related protein ATG5, NCOA4, Beclin1, and p62 in SKOV3 cells (C). ***P < 0.001 vs. Control, #P < 0.05 vs. ZnO-NPs Discussion ZnO-NPs exhibit excellent biocompatibility and unique physicochemical properties (Ibraheem et al. 2022), its roles in cancer diagnosis, targeted drug delivery, and therapy have been widely documented (Anjum et al. 2021). This study demonstrated that ZnO-NPs inhibited the malignant proliferation of SKOV3 cells and induce autophagy and ferroptosis in both in vivo and in vitro. Further research showed that ZnO-NPs induced ferroptosis in SKOV3 cells through an autophagy-dependent mechanism, which correlates with ATG5. Autophagy is conserved throughout the evolutionary process of eukaryotes and plays either a promotional or inhibitory role at different stages and in various environments of tumor development (Zhang et al. 2022). Previous studies have demonstrated in vitro that ZnO-NPs induce autophagy in SKOV3 cells and inhibit tumor cell proliferation, invasion, migration, and chemotherapy resistance (Gu and Yang 2023). However, due to differences between in vivo and in vitro environments, it remains unclear whether ZnO-NPs can induce autophagy and inhibit the malignant progression of OC in vivo. This study re-examined the effects of ZnO-NPs on autophagy and proliferation in SKOV3 cells in vitro. Consistent with previous findings, ZnO-NPs dose-dependently reduced SKOV3 cell proliferation, increased the expression of autophagic biomarkers LC3, Beclin1, and ATG5, and decreased p62 expression. Additionally, we validated the effects of ZnO-NPs in vivo using a xenograft tumor model. KI67, closely associated with cell proliferation, serves as a critical indicator of tumor cell malignant progression (Du et al. 2019). In vivo experimental results showed that treatment with ZnO-NPs reduced both the size of tumors and the extent of tissue damage, accompanied by decreased KI67 expression in tumor tissues. Furthermore, the expression of autophagy-related proteins LC3, Beclin1, ATG5, and p62 in tumor tissues from mice treated with ZnO-NPs showed a similar trend to that observed in vitro. These findings collectively suggest that ZnO-NPs inhibit malignant proliferation of SKOV3 cells and induce autophagy both in vitro and in vivo. Ferroptosis is a type of programmed cell death induced by iron-dependent oxidative damage (Otsuki et al. 2020). Excessive free Fe2+ in cells leads to significant ROS production via the Fenton or Haber-Weiss reactions, causing lipid peroxidation of polyunsaturated fatty acids in biological membranes. This compromises cell integrity directly, triggering programmed cell death (Yang et al. 2023). The accumulation of lipid ROS is a fundamental characteristic of ferroptosis, and the detection of oxidized lipid ROS can directly indicate whether ferroptosis is taking place (Gong et al. 2022). MDA and 4-HNE are common lipid peroxidation products that accumulate and disrupt cellular redox balance, thereby impairing membrane structure and function (Ren et al. 2021). SOD and GSH-Px, essential antioxidant enzymes, are critical defense mechanisms against oxidative stress and ferroptosis inhibition (Kang et al. 2021). This study shows that treatment with ZnO-NPs increased iron deposition, lipid peroxidation products, and oxidized lipid ROS levels, while decreasing SOD, GSH-Px, and non-oxidized lipid ROS levels in SKOV3 cells and tumor tissues. TFR1 controls cellular iron uptake (Lai et al. 2022), whereas ACSL4 aids in converting polyunsaturated fatty acids into acyl-CoA, which is a crucial substrate for lipid peroxidation (Liao et al. 2021). Treatment with ZnO-NPs significantly increased TFR1 and ACSL4 protein expression in SKOV3 cells and tumor tissues, while decreased the expression of ferroptosis crucial inhibitor GPX4 (Li et al. 2022). These results suggested that ZnO-NPs induced ferroptosis in OC cells in both laboratory and animal studies. Recent evidence suggests that autophagy mechanisms contribute to ferroptosis and ferroptosis is a process influenced by and dependent on autophagy (Mu et al. 2023). Despite ongoing exploration of its signaling and mechanisms, ADF has been recognized as an innovative antitumor strategy (Zhu et al. 2024). NCOA4 acts as a receptor facilitating ferritin autophagic degradation, thereby playing a crucial role in ferritinophagy (Mancias et al. 2014). Studies have shown that knocking down NCOA4 reduces Fe2+ accumulation and lipid peroxidation induced by ferroptosis (Hou et al. 2016). This study further investigated the relationship between ZnO-NPs induced autophagy and ferroptosis. The results showed a significant increase in NCOA4 expression in SKOV3 cells and tumor tissues in ZnO-NPs gruop. Based on this finding, we investigated whether ZnO-NPs-induced ferroptosis in SKOV3 cells was mediated by autophagy. Furthermore, the autophagy-related protein ATG5 exhibited a more prominent presence in ZnO-NPs-treated SKOV3 cells and mouse tumor tissues compared to other autophagy proteins. Therefore, we explored the role of ATG5 in ZnO-NPs-induced autophagy and ferroptosis. The study showed that the effects of ZnO-NPs on iron deposition and lipid peroxidation in SKOV3 cells were significantly reduced by autophagy inhibitor and si-ATG5, which reverse the expression of ferroptosis-related proteins. Moreover, ferroptosis inhibitor reversed the expression of autophagy-related proteins in ZnO-NPs-treated SKOV3 cells. This indicated that inhibition of ferroptosis also affected autophagy in ZnO-NPs-treated SKOV3 cells. However, ferroptosis inhibitor has a lesser impact on the autophagy of ZnO-NPs-treated SKOV3 cells (P < 0.05 or not significant) than the effect of autophagy inhibitors and si-ATG5 on the ferroptosis of ZnO-NPs-treated SKOV3 cells (P < 0.05, P < 0.01 or P < 0.001). Meanwhile, si-ATG5 demonstrated a more pronounced inhibitory effect on ferroptosis in ZnO-NPs-treated SKOV3 cells compared to the autophagy inhibitor 3-MA. And Therefore, it can be it tentatively considered that ZnO-NPs induced ferroptosis in SKOV3 cells through an autophagy-dependent mechanism, and was strongly correlating with ATG5. The study demonstrated that ZnO-NPs inhibited SKOV3 cell proliferation and induced ferroptosis by promoting autophagy through in vivo and in vitro experiments. These findings may provided a new evidence to comprehensively understand the anticancer mechanisms of ZnO-NPs and aid in its development and application.